Ionpath Names Goran Pljevaljcic as Chief Commercial Officer

Accomplished scientist and business executive brings nearly two decades of experience working on commercial strategies and operations in life sciences

MENLO PARK, Calif.--(BUSINESS WIRE)--Ionpath, a pioneer in high-definition spatial proteomics, announced today that Goran Pljevaljcic has joined the company as its Chief Commercial Officer. In this position, he will spearhead Ionpath’s commercial activities, including sales and marketing, to drive continued business growth and increase market share.

“With Ionpath’s recent strategic investment from Thermo Fisher Scientific, we are building a strong team that can continue scaling our business and capitalize on the growing momentum around our MIBIscope instruments and Spatial Proteomics Services,” said Sander Gubbens, CEO of Ionpath. “Goran has a stellar track record in commercial operations, business development, and corporate development and strategy. I look forward to working with him to support our current and future clients and to meet strategic objectives for our unique spatial proteomics platform.”

Pljevaljcic has two decades of experience in the life sciences, where he has worked in both industry and academia. Before joining Ionpath, he was Chief Commercial Officer at TwinStrand Biosciences, a developer of duplex sequencing technology. Prior to that, he held several senior positions at Bionano Genomics, including Vice President of Sales and Support, Vice President of Commercial Operations, and Director of Strategy and Corporate Development. He was instrumental in both Bionano Genomics’ IPO in 2018 and in driving the global adoption of Bionano’s optical genome mapping system to more than 160 placements. Before moving to industry, he was a staff scientist at Scripps Research and earned his PhD in chemistry from the University of Dortmund/Max Planck Institute of Molecular Physiology in Germany.

“I was drawn to Ionpath’s mission to improve human health by enabling actionable insights in translational research through spatial context,” said Pljevaljcic. “The company’s spatial proteomics technology is truly a game changer that is already yielding important results in immuno-oncology and other areas. I am proud to work with this team to provide customers with high-quality instruments and services that accelerate the path to precision medicine.”

About Ionpath

Ionpath, Inc., is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) platform breaks through the limitations of traditional immunohistochemistry, enabling a deeper understanding of the tissue microenvironment with highly multiplexed, quantitative single-cell analysis. With MIBI technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights for translational and clinical researchers at leading pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.